Abstract
Immune checkpoint inhibitors (ICI) have markedly changed the landscape of cancer therapy. By re-invigorating the immune system against tumors, ICI provide novel therapeutic options for a broad variety of malignancies, including many gastrointestinal (GI) cancers. However, these therapies can also induce autoimmune-like side effects in healthy tissue across the body. One of the most common of these side effects is ICI-mediated colitis and diarrhea (IMC). Here, we review the incidence and risk of IMC in ICI therapy, with a focus on what is known regarding IMC in patients with GI malignancies. We also discuss data available on the use of ICI and risk of IMC in patients with pre-existing inflammatory bowel disease, as these patients may have increased risk of IMC due to their underlying intestinal pathology.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 772-798 |
| Number of pages | 27 |
| Journal | World Journal of Gastrointestinal Oncology |
| Volume | 13 |
| Issue number | 8 |
| DOIs | |
| State | Published - 2021 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Keywords
- Cytotoxic T-lymphocyte antigen 4
- Gastrointestinal cancer
- Immune checkpoint inhibitors
- Inflammatory bowel disease
- Programmed cell death protein-1
